Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $20.53, but opened at $22.26. Structure Therapeutics shares last traded at $22.29, with a volume of 147,225 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GPCR. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

The company's 50-day moving average price is $25.31 and its 200 day moving average price is $32.33. The stock has a market cap of $1.21 billion, a PE ratio of -28.45 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics during the 4th quarter worth about $34,000. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth about $40,000. Finally, Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.